The Science of Chlamydia

Chlamydia has a distinctive biphasic life cycle that alternates between two morphological forms — a feature unique among bacteria:

• Elementary body (EB): The infectious, extracellular form. EBs are metabolically inert — they cannot replicate — but are structurally robust, with a highly cross-linked outer membrane that protects them outside a host cell. EBs attach to epithelial cells of the genital tract, conjunctiva, or respiratory tract and trigger their own uptake by receptor-mediated endocytosis.
• Reticulate body (RB): Once inside the host cell, the EB reorganises into the reticulate body — the metabolically active, replicating form. RBs are fragile and non-infectious; they live exclusively inside a membrane-bound vacuole called an inclusion. RBs replicate by binary fission over 18–20 hours, then reorganise back into EBs. The inclusion swells to contain hundreds of new EBs before it ruptures, releasing them to infect new cells or be transmitted to a new host.

The entire intracellular cycle takes approximately 48–72 hours, at which point the infected cell lyses and releases new EBs. In some circumstances, Chlamydia can enter a persistent state in which RBs remain alive but non-replicating — a form of intracellular dormancy thought to play a role in chronic and recurrent infections.

Living inside a vacuole within the host cell is not merely a metabolic necessity — it is also a sophisticated immune evasion strategy. By replicating inside the inclusion, Chlamydia effectively hides from many of the immune system's key surveillance mechanisms:

• Antibody neutralisation is only possible for the brief extracellular EB phase. Once inside the inclusion, antibodies cannot reach the pathogen.
• Chlamydia actively modifies the inclusion membrane to prevent it from fusing with lysosomes — the cellular compartments that would normally digest engulfed pathogens. This is mediated by a family of type III secretion system effector proteins that Chlamydia injects directly into the host cell.
• The bacterium downregulates the host cell's MHC class I presentation pathway, reducing the chances that infected cells are identified and killed by cytotoxic T lymphocytes.
• Chlamydia inhibits host cell apoptosis during early infection — keeping the cell alive long enough to complete its replication cycle — and then promotes it at the end to release new EBs.

The asymptomatic nature of most chlamydial infections is not accidental. Chlamydia has co-evolved with human hosts over millennia, and in that time a muted immune response has been selected for — both because an infected host that remains mobile and sexually active continues to transmit the bacterium, and because significant inflammatory responses cause the scarring that leads to serious complications.

The damage associated with chlamydia — pelvic inflammatory disease (PID), fallopian tube scarring, and tubal factor infertility — is largely immune-mediated. The bacterium itself does not produce a potent toxin; instead, repeated or prolonged infection drives a chronic inflammatory response. Heat shock protein 60 (HSP60), expressed by Chlamydia and sharing structural similarity with human HSP60, is thought to drive a cross-reactive immune response that damages the tubal epithelium even after the bacteria are cleared.

Chlamydia is exquisitely sensitive to antibiotics that inhibit protein synthesis — specifically tetracyclines (doxycycline) and macrolides (azithromycin). Because Chlamydia is an energy parasite that cannot synthesise its own ATP, and because it lives inside host cells that the antibiotics can penetrate, treatment is highly effective.

Unlike most bacteria, Chlamydia cannot acquire resistance genes by horizontal gene transfer as readily, and clinically significant antibiotic resistance has not emerged. However, doxycycline (7-day course) has been shown to be more effective than the single-dose azithromycin regimen for rectal chlamydia — an important distinction as rectal infections are common and often asymptomatic. Studies have also raised concerns that sub-therapeutic azithromycin exposures may promote a persistent phenotype, though this has not yet translated into clinical resistance.

The serovars L1, L2, and L3 of C. trachomatis cause LGV, a distinct disease from standard genital chlamydia. LGV serovars are more invasive — they infect macrophages and spread to lymph nodes, causing the dramatic swelling (buboes) and systemic inflammation associated with the condition. LGV is diagnosed through specific NAAT testing and requires a longer course of doxycycline (three weeks). It has been rising in prevalence among men who have sex with men in Europe and should be considered in any presentation of proctitis.